Valensa International obtains two US patents for joint health formulations

49e20df1-1551-4aa3-8258-f95e0101fefearticleimage.jpg

04 Oct 2017 --- The US Patent and Trademark Office has awarded Florida-based Valensa International two new patents, locking down patent protection for the core ingredients related to the company’s FlexPro MD and FlexPro ES. In clinical trials, these dietary formulations for joint health were shown to be three to five times more effective in relieving joint discomfort than a standard commercial formulation of glucosamine and chondroitin. 

The first of the two patents was granted for Flexuron Plus, Valensa’s proprietary, non-animal derived and highly-bioactive formula that features Medium-Chain Hyaluronic Acid (which has a lower molecular weight than traditional hyaluronic acid), when used in combination with the antioxidant Astaxanthin. Flexuron Plus is now available for licensing as a separate ingredient or finished product. 

The second patent was granted to Valensa for their bioavailable Zanthin Astaxanthin that has been coupled with Phospholipids. The Flexuron Plus blend of Zanthin Astaxanthin (a down-regulator of pro-inflammatory cytokines) and immunogenic hyaluronic acid, enhanced in the presence of phospholipid-based surfactants, has been clinically shown to dramatically reduce knee joint discomfort. In recent clinical trials, Valensa has demonstrated that this multi-patented blend works fast and has a cumulative beneficial effect over time on maximizing joint comfort.

Valensa’s joint formulations, including FlexPro MD and FlexPro ES, are available for multiple distribution channels, including retail mass market and specialty health stores.

According to Umasudhan C.P., CEO of Valensa, the ever-growing patent family protecting Flexuron Plus allows Valensa to develop the next generation of highly potent and mechanism-based joint formulations.

The human clinical study measuring the effectiveness of FlexPro MD, which contains Flexuron Plus, showed dramatic and nearly linear continuous improvement in joint discomfort over the 56-day clinical trial period. This trial showed that FlexPro MD was three to five times more effective in relieving joint discomfort than a standard commercial formulation of glucosamine and chondroitin (positive control arm) or the placebo control arm. Furthermore, joint discomfort began as early as seven days from trial initiation and by the end of the study subjects reported that they were essentially “pain-free.”

“Animal studies as well as in vitro cell culture work using real-time Polymerase Chain Reaction, or PCR, confirmed that our mechanism-based approach to product design was not only extremely effective and commercially rewarding, but also provided us with an extended vision into the design of even more potent and cost-effective next-generation joint healthcare products,” says Dr. John Minatelli, Sr. VP Business Development at Valensa who led the product development and clinical trials for FlexPro MD and Flexuron Plus.

In related news, Valensa International recently partnered up with Kemin Industries to jointly supply and market BetaVia ingredients, immune-supporting beta-glucans sourced from a proprietary strain of algae (Euglena gracilis), in the US dietary supplement and functional food and beverage markets. 

This partnership creates a two-armed sales approach to the US dietary supplement and functional foods and beverages markets. The Kemin sales team will service the functional food and beverage customers, while Valensa’s sales team will service customers producing dietary supplements.

“Valensa and its affiliate Parry Nutraceuticals are market leaders in microalgae-based supplements with well-established ingredient brands in over 30 countries,” Umasudhan C.P. says about the partnership. “The relationship with Kemin allows us to introduce novel immunity supplement formulations made stronger by BetaVia, to our omnichannel customer base in the US and internationally.”

Related Articles

Nutrition & Health News

Researchers create app to predict and intervene in users' overeating

13 Dec 2017 --- Researchers at Worcester Polytechnic Institute (WPI) and the University of Connecticut (UConn) are collaborating on a smartphone app aimed at helping users manage their overeating challenges in three key ways: by tracking eating patterns, providing interventions and helping change behavior. According to the researchers, the app and its distinctive methodology have shown “tremendous promise” in an early pilot study.

Nutrition & Health News

Dairy proteins take center stage at FiE 2017

12 Dec 2017 --- Exhibitors at FiE 2017 in Frankfurt showed a sustained focus on high protein concepts, with a number of notable innovations in the area of dairy-related ingredients. NutritionInsight looks at just a few of the offerings showcased at this year’s event.

Nutrition & Health News

Energetic growth: Energy boosters add pep to the nutritional space’s step

11 Dec 2017 --- Busy schedules can cause consumers to go through an “energy crisis” – prompting their desire to reach for products that might offer some support to their energy levels. Energy boosters are certainly showing signs of growth in all regions tracked by Innova Market Insights. A CAGR in supplement launches of +208.8 percent in South America from 2012 to 2016 is particularly noteworthy, while Europe is top of the pile worldwide with 28.8 percent of its supplement launches having an energy claim in 2016 and its CAGR amounting to a strong +86.7 percent.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

More Articles
URL : http://www.nutritioninsight.com:80/news/valensa-international-obtains-two-us-patents-for-joint-health-formulations.html